1-3 of 3
Jun Imagawa, MD
Close
Sort by
Journal Articles

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Hideo Tanaka, MD, PhD, Jun Imagawa, MD, PhD, Masaya Okada, MD, PhD, Hirohisa Nakamae, MD, PhD, Masayuki Hino, MD, PhD, Kazunori Murai, MD, PhD, Yoji Ishida, M.D., Ph.D., Takashi Kumagai, MD, PhD, Seiichi Sato, MD, Kazuteru Ohashi, MD, PhD, Hisashi Sakamaki, MD, PhD, Hisashi Wakita, MD, PhD, Nobuhiko Uoshima, MD, PhD, Yasunori Nakagawa, MD, Yosuke Minami, MD, PhD, Masahiro Ogasawara, MD, PhD, Tomoharu Takeoka, MD, Hiroshi Akasaka, MD, Satoshi Morita, PhD, Junichi Sakamoto, MD, PhD, Shinya Kimura, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3998.
https://doi.org/10.1182/blood.V122.21.3998.3998
Published: 2013
Journal Articles

BMI1 Collaborates with RUNX1/AML1 Mutants in the Development of Human Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML)

Hironori Harada, MD, Ye Ding, MD, Jun Imagawa, MD, Takahiko Miyama, MD, Akiro Kimura, MD, Yuka Harada, MD
Journal: Blood
Blood (2011) 118 (21): 275.
https://doi.org/10.1182/blood.V118.21.275.275
Published: 2011
Journal Articles

AML1/RUNX1 Point Mutation Possibly Promotes Leukemic Transformation in Myeloproliferative Disorders.

Jun Imagawa, MD, Yuka Harada, MD, Ye Ding, MD, Akiro Kimura, MD, PhD, Hironori Harada, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1902.
https://doi.org/10.1182/blood.V114.22.1902.1902
Published: 2009